Andrim Halili, Talip E Eroglu, Christian Torp-Pedersen, Bochra Zareini
{"title":"Statin use for primary prevention of cardiovascular disease among apparently healthy adults.","authors":"Andrim Halili, Talip E Eroglu, Christian Torp-Pedersen, Bochra Zareini","doi":"10.1093/eurjpc/zwaf357","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To study the association between statin adherence and the 5-year risk of major cardiovascular events among apparently healthy individuals.</p><p><strong>Methods and results: </strong>A nationwide cohort study utilising national registries in Denmark was conducted. All apparently healthy individuals aged 40-85 years using statins for one year between 1997 and 2022 with no personal history of cardiovascular diseases, diabetes mellitus, chronic obstructive pulmonary disease, hepatic diseases, cancer, or parents with cardiovascular disease, among other exclusion factors, were included. Statin use was categorized according to adherence by the proportion of days covered with redeemed statin prescriptions: <50% (low), 50-75% (moderate), and 75-100% (high). The primary outcome was a composite of myocardial infarction, stroke, or cardiovascular death. The 5-year absolute risk was estimated using the Aalen-Johansen estimator while considering competing risks. Additionally, cause-specific Cox proportional hazards models were used to estimate hazard ratios across statin adherence levels.Among 151,791 apparently healthy individuals, low statin adherence was associated with a 5-year major cardiovascular risk of 4.77% (95%-confidence interval 4.18-5.36). For moderate adherence, the 5-year risk was 3.71% (95%-confidence interval 4.18-5.36), and the corresponding hazard ratio was 0.87 (95%-confidence interval 0.75-1.01), while high adherence was associated with the lowest 5-year risk of 3.01% (95%-confidence interval 2.90-3.11), and the corresponding hazard ratio was 0.66 (95%-confidence interval 0.58-0.75).</p><p><strong>Conclusion: </strong>High statin adherence among apparently healthy users was associated with a significant risk reduction of major cardiovascular adverse events.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of preventive cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurjpc/zwaf357","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To study the association between statin adherence and the 5-year risk of major cardiovascular events among apparently healthy individuals.
Methods and results: A nationwide cohort study utilising national registries in Denmark was conducted. All apparently healthy individuals aged 40-85 years using statins for one year between 1997 and 2022 with no personal history of cardiovascular diseases, diabetes mellitus, chronic obstructive pulmonary disease, hepatic diseases, cancer, or parents with cardiovascular disease, among other exclusion factors, were included. Statin use was categorized according to adherence by the proportion of days covered with redeemed statin prescriptions: <50% (low), 50-75% (moderate), and 75-100% (high). The primary outcome was a composite of myocardial infarction, stroke, or cardiovascular death. The 5-year absolute risk was estimated using the Aalen-Johansen estimator while considering competing risks. Additionally, cause-specific Cox proportional hazards models were used to estimate hazard ratios across statin adherence levels.Among 151,791 apparently healthy individuals, low statin adherence was associated with a 5-year major cardiovascular risk of 4.77% (95%-confidence interval 4.18-5.36). For moderate adherence, the 5-year risk was 3.71% (95%-confidence interval 4.18-5.36), and the corresponding hazard ratio was 0.87 (95%-confidence interval 0.75-1.01), while high adherence was associated with the lowest 5-year risk of 3.01% (95%-confidence interval 2.90-3.11), and the corresponding hazard ratio was 0.66 (95%-confidence interval 0.58-0.75).
Conclusion: High statin adherence among apparently healthy users was associated with a significant risk reduction of major cardiovascular adverse events.
期刊介绍:
European Journal of Preventive Cardiology (EJPC) is an official journal of the European Society of Cardiology (ESC) and the European Association of Preventive Cardiology (EAPC). The journal covers a wide range of scientific, clinical, and public health disciplines related to cardiovascular disease prevention, risk factor management, cardiovascular rehabilitation, population science and public health, and exercise physiology. The categories covered by the journal include classical risk factors and treatment, lifestyle risk factors, non-modifiable cardiovascular risk factors, cardiovascular conditions, concomitant pathological conditions, sport cardiology, diagnostic tests, care settings, epidemiology, pharmacology and pharmacotherapy, machine learning, and artificial intelligence.